Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

DNMT3A wt NPM1-Mutation Defines a Subgroup of MDS with Special Favorable Outcomes Towards Decitabine Therapy

Lingyun Wu, MD PhD, Xiao Li, MD, Feng Xu, He Qi, Zheng Zhang, Dong Wu, Luxi Song, MD, Liyu Zhou, Chao Xiao, Jiying Su, Juan Guo, Chunkang Chang

Blood (2019) 134 (Supplement_1): 1724.

https://doi.org/10.1182/blood-2019-124008

Published: 2019

Journal Articles

Reduction of Dicer1 By Multiple Myeloma Cells in Mesenchymal Stem Cells Promotes Cellular Senescence and Tumor-Supporting Effect and Decreases the Differentiation

Juan Guo, Xiao Li, MD, Youshan Zhao, Chengming Fei, Chunkang Chang, PhD, Sida Zhao, Qingqing Zheng

Blood (2017) 130 (Supplement 1): 4399.

https://doi.org/10.1182/blood.V130.Suppl_1.4399.4399

Published: 2017

Journal Articles

Iron Overload Injures the Function of MDS-Derived Mesenchymal Stromal Cells through Activating the Ampkα/Mff/Drp1 Signaling Pathway

Qingqing Zheng, Xiao Li, MD, Chunkang Chang, PhD

Blood (2017) 130 (Supplement 1): 5268.

https://doi.org/10.1182/blood.V130.Suppl_1.5268.5268

Published: 2017

Journal Articles

Dysregulation of ANKRD11 Influenced Hematopoisis By Histone Acetylation-Mediated Gene Expression in Myelodysplastic Syndrome

Youshan Zhao, MD, Feng Xu, Juan Guo, MD, Sida Zhao, MD, Chunkang Chang, MD PhD, Xiao Li, MD PhD

Blood (2016) 128 (22): 4292.

https://doi.org/10.1182/blood.V128.22.4292.4292

Published: 2016

Journal Articles

Ribosomal Protein L23 Negatively Regulates Cell Apoptosis Via Its Suppression of Miz1 and Activation c-Myc in Higher-Risk Myelodysplastic Syndromes

Yuekun Qi, Lingyun Wu, Chunkang Chang, MD PhD, Feng Xu, Qi He, Xiao Li, MD PhD

Blood (2016) 128 (22): 5508.

https://doi.org/10.1182/blood.V128.22.5508.5508

Published: 2016

Journal Articles

Activation of Notch-Hes Signaling Pathway Impairs Osteogenic Differentiation and Hematopoietic Stem Cell-Supporting Capacitiy of Mesenchymal Stromal Cells Derived from Myelodysplastic Syndromes Patients

Chunkang Chang, MDPhD, Chengming Fei, MD, Juan Guo, MD, Youshan Zhao, MD, Shucheng Gu, MD, Xiao Li, MD PhD

Blood (2015) 126 (23): 2857.

https://doi.org/10.1182/blood.V126.23.2857.2857

Published: 2015

Journal Articles

A Primary Study of the Gene Mutations in Predicting Treatment Response to Decitabine in Patients with MDS

Chunkang Chang, MDPhD, Youshan Zhao, MD, Feng Xu, Xiao Li, MD PhD

Blood (2015) 126 (23): 1689.

https://doi.org/10.1182/blood.V126.23.1689.1689

Published: 2015

Journal Articles

Labile Plasma Iron (LPI), More Practical and More Sensitive to Iron Overload in Myelodysplastic Syndromes

Chunkang Chang, MDPhD, Shucheng Gu, MD, Juan Guo, MD, Youshan Zhao, MD, Chengming Fei, MD, Xiao Li, MD PhD

Blood (2015) 126 (23): 5230.

https://doi.org/10.1182/blood.V126.23.5230.5230

Published: 2015

Journal Articles

Chidamide, a Novel Histone Deacetylase Inhibitor, Displays Potent Antitumor Activity Against MDS Cells Mainly through JAK2/STAT3 Signaling Inhibition

Chunkang Chang, MDPhD, Sida Zhao, MD, Juan Guo, MD, Youshan Zhao, MD, Chengming Fei, MD, Shucheng Gu, MD, Xiao Li, MD PhD

Blood (2015) 126 (23): 5233.

https://doi.org/10.1182/blood.V126.23.5233.5233

Published: 2015

Journal Articles

DHX9 Mutations Are Identified As a Novel Recurrent Event in Patients with Myelodysplastic Syndromes and Closely Related to Bone Marrow Failure

Wenhui Shi, Feng Xu, Chunkang Chang, MDPhD, Xiao Li, MD PhD

Blood (2015) 126 (23): 1651.

https://doi.org/10.1182/blood.V126.23.1651.1651

Published: 2015

Journal Articles

EZH2-Mediated Activation of Serine Biosynthetic Pathway Is Critical for Resistance of Clonal Cells to Stress-Related Apoptosis in Low-Grade Myelodysplastic Syndrome

Feng Xu, Chunkang Chang, MDPhD, Wenhui Shi, Xiao Li, MD PhD

Blood (2015) 126 (23): 1660.

https://doi.org/10.1182/blood.V126.23.1660.1660

Published: 2015

Journal Articles

Downregulation of Dicer1 Promotes Cellular Senescence and Decreases the Differentiation and Stem Cell-Supporting Capacities of MSCs in Patients with Myelodysplastic Syndrome

Youshan Zhao, Dong Wu, Chengming Fei, Juan Guo, Shucheng Gu, Feng Xu, Zheng Zhang, Chunkang Chang, Xiao Li, MD PhD

Blood (2014) 124 (21): 4365.

https://doi.org/10.1182/blood.V124.21.4365.4365

Published: 2014

Journal Articles

Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP)

Xin Du, MD, Jie Jin, MD, Zhen Cai, MD, Fangping Chen, MD, Dao-bin Zhou, MD, Li Yu, MD, Xiaoyan Ke, MD PhD, Xiao Li, MD PhD, Depei Wu, MD, Fanyi Meng, MD, Dena DeMarco, Jingshan Zhang, PhD, Jay Mei, MD, Jian Hou, MD PhD

Blood (2014) 124 (21): 5737.

https://doi.org/10.1182/blood.V124.21.5737.5737

Published: 2014

Journal Articles

Identification of microRNA-Regulated Pathways through a Integration of Mcrorna-mRNA Microarray and Bioinformatics Analysis in CD34+ Cells of Myelodysplastic Syndromes

Xiao Li, MD PhD, Xu Feng, MD PhD, Chunkang Chang, Qi He, Wu Lingyun

Blood (2014) 124 (21): 3238.

https://doi.org/10.1182/blood.V124.21.3238.3238

Published: 2014

Journal Articles

Efficacy and Safety Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment: MM-021 Subgroup Analysis

Dao-bin Zhou, MD, Li Yu, MD, Xin Du, MD, Jie Jin, MD, Zhen Cai, MD, Fangping Chen, MD, Xiao Li, MD, PhD, Depei Wu, MD, Fanyi Meng, MD, Huisheng Ai, MMed, Jingshan Zhang, PhD, Honeylet Wortman-Vayn, Jay Mei, MD, Jianmin Wang, MD, Jian Hou, MD, PhD

Blood (2013) 122 (21): 5374.

https://doi.org/10.1182/blood.V122.21.5374.5374

Published: 2013

Journal Articles

The MM-021 Trial Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma: Impact Of Prior Therapies On Efficacy and Safety

Jie Jin, MD, Xin Du, MD, Zhen Cai, MD, Fangping Chen, MD, Dao-bin Zhou, MD, Li Yu, MD, Xiao Li, MD, PhD, Depei Wu, MD, Fanyi Meng, MD, Huisheng Ai, MMed, Jianmin Wang, MD, Jingshan Zhang, PhD, Honeylet Wortman-Vayn, Jay Mei, MD, Jian Hou, MD, PhD

Blood (2013) 122 (21): 3227.

https://doi.org/10.1182/blood.V122.21.3227.3227

Published: 2013

Journal Articles

Efficacy and Toxicity Of Decitabine Versus CHG Priming Regimen In Patients With Higher Risk Myelodysplastic Syndrome

Lingyun Wu, Xiao Li, MD, PhD, Feng Xu, Chunkang Chang, Qi He, Zheng Zhang, Luxi Song, Xi Zhang, Jiying Su, Liyu Zhou

Blood (2013) 122 (21): 2789.

https://doi.org/10.1182/blood.V122.21.2789.2789

Published: 2013

Journal Articles

Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression Level Is a Potential Predictive Tool For Response To Decitabine In Patients With Myelodysplastic Syndrome

Lingyun Wu, Xiao Li, MD, PhD, Chunkang Chang, Feng Xu, Qi He, Dong Wu, Jiying Su

Blood (2013) 122 (21): 2790.

https://doi.org/10.1182/blood.V122.21.2790.2790

Published: 2013

Journal Articles

Clinical Observation Of Decitabine Treatment In Selected Patients With Lower Risk Myelodysplastic Syndromes

Chunkang Chang, Zheng Zhang, Youshan Zhao, Xiao Li, MD, PhD

Blood (2013) 122 (21): 5202.

https://doi.org/10.1182/blood.V122.21.5202.5202

Published: 2013

Journal Articles

Protein-Coding and Non-Coding RNA Expression Profiles Of Mesenchymal Stem Cells In Patients With Myelodysplastic Syndromes

Youshan Zhao, Chunkang Chang, Xiao Li, MD, PhD

Blood (2013) 122 (21): 1572.

https://doi.org/10.1182/blood.V122.21.1572.1572

Published: 2013

NARROW

DNMT3A wt NPM1-Mutation Defines a Subgroup of MDS with Special Favorable Outcomes Towards Decitabine Therapy

Reduction of Dicer1 By Multiple Myeloma Cells in Mesenchymal Stem Cells Promotes Cellular Senescence and Tumor-Supporting Effect and Decreases the Differentiation

Iron Overload Injures the Function of MDS-Derived Mesenchymal Stromal Cells through Activating the Ampkα/Mff/Drp1 Signaling Pathway

Dysregulation of ANKRD11 Influenced Hematopoisis By Histone Acetylation-Mediated Gene Expression in Myelodysplastic Syndrome

Ribosomal Protein L23 Negatively Regulates Cell Apoptosis Via Its Suppression of Miz1 and Activation c-Myc in Higher-Risk Myelodysplastic Syndromes

Activation of Notch-Hes Signaling Pathway Impairs Osteogenic Differentiation and Hematopoietic Stem Cell-Supporting Capacitiy of Mesenchymal Stromal Cells Derived from Myelodysplastic Syndromes Patients

A Primary Study of the Gene Mutations in Predicting Treatment Response to Decitabine in Patients with MDS

Labile Plasma Iron (LPI), More Practical and More Sensitive to Iron Overload in Myelodysplastic Syndromes

Chidamide, a Novel Histone Deacetylase Inhibitor, Displays Potent Antitumor Activity Against MDS Cells Mainly through JAK2/STAT3 Signaling Inhibition

DHX9 Mutations Are Identified As a Novel Recurrent Event in Patients with Myelodysplastic Syndromes and Closely Related to Bone Marrow Failure

EZH2-Mediated Activation of Serine Biosynthetic Pathway Is Critical for Resistance of Clonal Cells to Stress-Related Apoptosis in Low-Grade Myelodysplastic Syndrome

Downregulation of Dicer1 Promotes Cellular Senescence and Decreases the Differentiation and Stem Cell-Supporting Capacities of MSCs in Patients with Myelodysplastic Syndrome

Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP)

Identification of microRNA-Regulated Pathways through a Integration of Mcrorna-mRNA Microarray and Bioinformatics Analysis in CD34+ Cells of Myelodysplastic Syndromes

Efficacy and Safety Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment: MM-021 Subgroup Analysis

The MM-021 Trial Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma: Impact Of Prior Therapies On Efficacy and Safety

Efficacy and Toxicity Of Decitabine Versus CHG Priming Regimen In Patients With Higher Risk Myelodysplastic Syndrome

Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression Level Is a Potential Predictive Tool For Response To Decitabine In Patients With Myelodysplastic Syndrome

Clinical Observation Of Decitabine Treatment In Selected Patients With Lower Risk Myelodysplastic Syndromes

Protein-Coding and Non-Coding RNA Expression Profiles Of Mesenchymal Stem Cells In Patients With Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only